Literature DB >> 23792334

Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary.

Monika A Jarzabek1, Kieron J Sweeney, Rhys L Evans, Andreas H Jacobs, Roger Stupp, Donncha O'Brien, Mitchel S Berger, Jochen H M Prehn, Annette T Byrne.   

Abstract

Current therapeutic strategies against glioblastoma (GBM) have failed to prevent disease progression and recurrence effectively. The part played by molecular imaging (MI) in the development of novel therapies has gained increasing traction in recent years. For the first time, using expertise from an integrated multidisciplinary group of authors, herein we present a comprehensive evaluation of state-of-the-art GBM imaging and explore how advances facilitate the emergence of new treatment options. We propose a novel next-generation treatment paradigm based on the targeting of multiple hallmarks of cancer evolution that will heavily rely on MI.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23792334     DOI: 10.1016/j.drudis.2013.06.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  7 in total

Review 1.  Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma.

Authors:  Shin-Yi Liu; Ming-Fu Chiang; Yu-Jen Chen
Journal:  Exp Biol Med (Maywood)       Date:  2014-11-27

2.  Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

Authors:  Christine Lu-Emerson; Dan G Duda; Kyrre E Emblem; Jennie W Taylor; Elizabeth R Gerstner; Jay S Loeffler; Tracy T Batchelor; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2015-02-23       Impact factor: 44.544

3.  Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.

Authors:  Xiao Bao; Ming-Wei Wang; Yong-Ping Zhang; Ying-Jian Zhang
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

4.  Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.

Authors:  M A Jarzabek; V Amberger-Murphy; J J Callanan; C Gao; A M Zagozdzon; L Shiels; J Wang; K L Ligon; B E Rich; P Dicker; W M Gallagher; J H M Prehn; A T Byrne
Journal:  Br J Cancer       Date:  2014-11-06       Impact factor: 7.640

5.  DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance.

Authors:  Juliana Ferreira de Sousa; Rodolfo Bortolozo Serafim; Laura Marise de Freitas; Carla Raquel Fontana; Valeria Valente
Journal:  Genet Mol Biol       Date:  2019-12-13       Impact factor: 1.771

6.  Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.

Authors:  Peng Xu; Handong Wang; Hao Pan; Jiakai Chen; Chulei Deng
Journal:  Cancer Chemother Pharmacol       Date:  2022-01-08       Impact factor: 3.288

7.  PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging.

Authors:  Christopher P Irwin; Yasiri Portorreal; Christian Brand; Yachao Zhang; Pooja Desai; Beatriz Salinas; Wolfgang A Weber; Thomas Reiner
Journal:  Neoplasia       Date:  2014-06-23       Impact factor: 5.715

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.